CSPC Pharmaceutical Group Limited (CSPCY)
OTCMKTS · Delayed Price · Currency is USD
5.25
+0.44 (9.19%)
Aug 29, 2025, 3:59 PM EDT
CSPC Pharmaceutical Group Revenue
CSPC Pharmaceutical Group had revenue of 6.26B CNY in the quarter ending June 30, 2025, a decrease of -14.28%. This brings the company's revenue in the last twelve months to 26.00B, down -17.87% year-over-year. In the year 2024, CSPC Pharmaceutical Group had annual revenue of 29.01B, down -7.76%.
Revenue (ttm)
26.00B CNY
Revenue Growth
-17.87%
P/S Ratio
4.07
Revenue / Employee
1.21M CNY
Employees
21,400
Market Cap
14.77B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 29.01B | -2.44B | -7.76% |
Dec 31, 2023 | 31.45B | 513.21M | 1.66% |
Dec 31, 2022 | 30.94B | 3.07B | 11.02% |
Dec 31, 2021 | 27.87B | 2.92B | 11.73% |
Dec 31, 2020 | 24.94B | 2.84B | 12.84% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 221.55M |
Elite Pharmaceuticals | 105.45M |
Northwest Biotherapeutics | 1.09M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
Global Cord Blood | 196.10M |
CSPC Pharmaceutical Group News
- 4 weeks ago - Madrigal in-pact with CSPC Pharma for obesity drug license - Seeking Alpha
- 2 months ago - Medtide Launches Hong Kong IPO to Boost Weight-loss Business - Benzinga
- 2 months ago - AstraZeneca Inks China AI Research Deal For Chronic Diseases - NDTV
- 2 months ago - AstraZeneca Inks Research Pact With China's CSPC Pharmaceuticals Focused On AI-Driven Research, Valued Up To $5.33 Billion - Benzinga
- 2 months ago - AstraZeneca signs US$5 billion research deal with China’s CSPC - BNN Bloomberg
- 2 months ago - CSPC Pharma Pursues Licensing Deals After Lackluster Earnings - Benzinga
- 3 months ago - Chinese biotech’s mega drug-licensing deals with multinationals surge - South China Morning Post
- 10 months ago - CSPC Pharmaceutical Group Limited goes ex dividend tomorrow - Seeking Alpha